Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KRP203 in active treatment-refractory subacute cutaneous lupus erythematosus
2010-019689-10Phase 2Terminated
- Sponsor
- Novartis
- Start
- Aug 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in subacute cutaneous lupus erythematosus (SCLE) comparing KRP203 with Placebo (2 arms). Primary endpoint: Mean difference from baseline in CLASI activity score. Started Aug 2010; status: terminated.
02
Drugs
mocravimod
03
Conditions
subacute cutaneous lupus erythematosus (SCLE)
Beyond the preview
Go deeper on 2010-019689-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019689-10.